상세 보기
Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC)
- Sun, M.;
- Spigel, D. R.;
- Lee, Y-J.;
- Yoon, H.;
- Liu, Y.;
- ... Lee, G-W.;
- 외 11명
Citations
WEB OF SCIENCE
0- 제목
- Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC)
- 저자
- Sun, M.; Spigel, D. R.; Lee, Y-J.; Yoon, H.; Liu, Y.; Ahern, E.; Harris, S.; Lee, G-W.; Yan, D.; Chen, J.; Shiah, H-S.; Deng, T.; Zheng, H.; Tan, W.; Zhou, Z.; Wang, R.; Ba, Y.
- 발행일
- 2023-10
- 유형
- Meeting Abstract
- 권
- 34
- 페이지
- S862 ~ S863